Shalina Healthcare S.A.R.L.
Business Opportunity Assessment Report

Company Snapshot

Shalina Healthcare S.a.r.l. is a legally registered entity domiciled in the Democratic Republic of the Congo, operating as a specialized pharmaceutical distributor. Its core business revolves around importing finished dosage forms—primarily generic medicines and therapeutic formulations—for regional distribution across Central and East Africa. The company functions exclusively as a downstream trade intermediary with no evidence of manufacturing, branding, or retail operations. A notable structural feature is its near-total reliance on Indian suppliers (98.2% of transactions), with all procurement activity concentrated within a tightly defined set of HS codes for medicinal products. A clear operational shift occurred in late 2024: transaction volume surged by 63% MoM from December 2024 to January 2025, coinciding with expanded sourcing from UAE-based entities and port diversification beyond JNPT.

Company Attribute Information

Trade Trend Analysis

Data interpretation reveals extreme temporal volatility: monthly transaction volumes swing between 440K and 71M units — a 160-fold range — with two distinct peaks in July 2023 (70.9M) and December 2025 (18.8M), both followed by sharp contractions. This pattern reflects batch-driven, campaign-style procurement rather than steady replenishment, likely aligned with public health tenders or seasonal disease outbreaks. The abrupt 83% drop from July to August 2023 signals supply chain fragility or contract expiration risk. Transaction volume contraction after peak months indicates high dependency on time-bound procurement cycles — a structural vulnerability in tender-dependent markets.

Trade Partner Analysis

Data interpretation shows overwhelming concentration: Shalina Laboratories Pvt Ltd (India) accounts for 92.7% of all transactions — a near-monopoly supplier relationship spanning over 10,200 shipments. The remaining 7.3% is fragmented across 9 other Indian and UAE-based entities, all bearing 'Shalina' in their names — suggesting intra-group coordination or brand-aligned sourcing. No non-affiliated third-party suppliers appear in top 20, indicating tightly controlled, vertically aligned procurement architecture. High single-supplier dependency creates acute supply continuity risk — especially given that the second-largest partner (Shalina Healthcare Ltd.) has been inactive since April 2024.

HS Code Analysis

Data interpretation highlights therapeutic specialization: Top 10 HS codes collectively cover 71.6% of all transactions and map precisely to WHO Essential Medicines List categories — notably antidiabetics (30049029), ACE inhibitors (30049069), NSAIDs (30049099), and broad-spectrum antibiotics (30043200). The presence of 300490000000 (unspecified medicinal products) and 300450000000 (hormonal preparations) among newly active codes signals recent portfolio expansion into chronic disease management and endocrinology. Therapeutic focus on high-prevalence NCDs aligns with DRC’s national health priorities — but also exposes exposure to regulatory tightening on generic quality assurance.

Trade Region Analysis

Data interpretation confirms geographic singularity: India dominates with 98.2% of transaction count and virtually 100% of transaction value — a level of regional concentration rarely seen outside captive supply chains. UAE appears solely as a logistics/registration hub (1.8% of count, zero volume share), while China’s 0.03% reflects negligible trial sourcing. No African, European, or American suppliers appear in top 20, confirming absence of local or diversified sourcing. Absolute reliance on a single foreign jurisdiction introduces dual risk: Indian export policy shifts and DRC–India bilateral trade friction could halt operations overnight.

Export Port Analysis

Data interpretation shows logistical consolidation: JNPT (Jawaharlal Nehru Port Trust) handles nearly half (49.2%) of all shipments — consistent with its status as India’s largest container port and primary gateway for pharmaceutical exports. The emergence of ‘Jawaharlal Nehru (Nhava Sheva)’ as a distinct entry (18.1%) — alongside legacy variants like ‘Nhava Sheva Sea’ and ‘JNPT/Nhava Sheva Sea’ — signals formalized port naming standardization and growing use of integrated multimodal terminals. Air cargo entries (Bombay Air, Sahar Air) remain marginal (<0.5%), confirming sea freight dominance. Port concentration at JNPT increases exposure to infrastructure bottlenecks — especially during monsoon season or labor disruptions.

Contact Information

• Official Website: Not found
• LinkedIn: Not found
• Facebook / Twitter / Instagram: Not found
• Email / Phone: Not publicly available
• Registered Address: Not disclosed

Company Trade Summary

• Operates exclusively as a pharmaceutical distributor — no evidence of manufacturing, branding, or retail.
• 92.7% of procurement is consolidated under one Indian supplier (Shalina Laboratories Pvt Ltd.), indicating high control but also high risk.
• HS code profile confirms specialization in essential generic medicines for diabetes, hypertension, infection, and inflammation.
• Near-total dependence on Indian exports (98.2%) and JNPT port (49.2%) creates systemic supply chain vulnerability.
• Recent diversification into UAE-based entities and new HS codes suggests strategic expansion into chronic disease therapeutics.